New price gets Clovis’ PARP inhibitor on the CDFNICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to Share XNew price gets Clovis’ PARP inhibitor on the CDFhttps://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/
GSK joins with US biotech to toughen up cell therapies for solid tumoursGlaxoSmithKline has announced a five-year collaboration with San Francisco biotech Lyell Immunopharma, to strengthen therapeutic T-cells before they Share XGSK joins with US biotech to toughen up cell therapies for solid tumourshttps://pharmaphorum.com/news/gsk-joins-with-us-biotech-to-toughen-up-cell-therapies-for-solid-tumours/
Owkin’s machine learning tech to inform mesothelioma trialsA mesothelioma prognostic model from medical machine learning firm Owkin has been showcased in the journal Nature, and Share XOwkin’s machine learning tech to inform mesothelioma trialshttps://pharmaphorum.com/news/owkins-machine-learning-tech-gives-mesothelioma-prognosis-and-survival-insights/
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomaThe Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few Share XScotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomahttps://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/
Merck and Co’s cancer drug Keytruda to smash sales records by 2023 – forecastMerck & Co’s Keytruda cancer immunotherapy is set to become the world’s top-selling drug by annual revenue in Share XMerck and Co’s cancer drug Keytruda to smash sales records by 2023 – forecasthttps://pharmaphorum.com/news/mercks-cancer-drug-keytruda-to-smash-sales-records-by-2023-forecast/
NICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBCNICE has said Roche’s Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a Share XNICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBChttps://pharmaphorum.com/news/nice-says-no-to-regular-nhs-funding-for-roches-tecentriq-in-tnbc/
Merck & Co hopes for foothold in early TNBC after Keytruda trial winMerck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold Share XMerck & Co hopes for foothold in early TNBC after Keytruda trial winhttps://pharmaphorum.com/news/merck-co-hopes-for-foothold-in-early-tnbc/
ESMO 2019 – new data could unlock bigger market for PARP inhibitorsAstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as Share XESMO 2019 – new data could unlock bigger market for PARP inhibitorshttps://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/
ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengeAmgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported Share XESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challengehttps://pharmaphorum.com/news/esmo-2019-amgens-kras-drug-finds-colorectal-cancer-a-challenge/
As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer dataGlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the Share XAs ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer datahttps://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/
J&J gets okay for a third first-line Darzalex combo in USJohnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting Share XJ&J gets okay for a third first-line Darzalex combo in UShttps://pharmaphorum.com/news/jj-gets-okay-for-a-third-first-line-darzalex-combo-in-us/
Immunicum continues cell therapy trials after positive kidney cancer readoutSweden’s Immunicum has announced detailed results from its mid-stage trial of its oncology cell-based immunotherapy ilixadencel, which it Share XImmunicum continues cell therapy trials after positive kidney cancer readouthttps://pharmaphorum.com/news/immunicum-to-push-on-with-immunotherapy/
Clovis signs radiopharmaceuticals R&D deal with German biotech 3BClovis Oncology has become the latest pharma to invest in radiopharmaceuticals, signing a licensing and collaboration deal with Share XClovis signs radiopharmaceuticals R&D deal with German biotech 3Bhttps://pharmaphorum.com/news/clovis-signs-radiopharmaceuticals-rd-deal-with-german-biotech-3b/
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EUBayer’s TRK inhibitor Vitrakvi has been approved by the EMA, becoming the first therapy for cancer based on Share XBayer’s Vitrakvi is first tumour-agnostic drug approved in EUhttps://pharmaphorum.com/news/bayers-vitrakvi-is-first-tumour-agnostic-drug-approved-in-eu/
Smartphone app provides skin cancer early warning serviceThe makers of a smartphone app are hoping that it could be used to play a crucial role Share XSmartphone app provides skin cancer early warning servicehttps://pharmaphorum.com/news/smartphone-app-provides-skin-cancer-early-warning-service/
